Newsroom

Takeda Receives Complete Response Letter from U.S. FDA for the Investigational Subcutaneous Formulation of ENTYVIO^® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn’s Disease Management

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019

Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61^st American Society of Hematology (ASH) Annual Meeting

First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda’s Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints